CLAIMS

IN THE CLAIMS:

This listing of the claims will replace all prior versions, and listing, of claims in the application or previous response to office action:

1-30. (Canceled).

31. (New) A pharmaceutical composition comprising:

at least one Mucuna pruriens seed component, substance, fraction, or mixture thereof obtained therefrom; and

a pharmaceutically acceptable diluent, excipient or carrier.

32. (New) The pharmaceutical composition of claim 31, wherein the component, substance, fraction, or mixture thereof comprise at least one extract from a Mucuna pruriens seed.

33. (New) The pharmaceutical composition of claim 31, wherein the component, substance, fraction, or mixture thereof comprises at least one bipolar-lipophilic molecule.

34. (New) The pharmaceutical composition of claim 31, wherein the component, substance, fraction or mixture thereof is selected from the group consisting of alkaloids, proteins, peptides, polysaccharides, glycosides, glycoproteins, sterols, phophatids, fatty acids, amino acids, and any combination thereof.

35. (New) The pharmaceutical composition of claim 31, wherein the pharmaceutical composition is formulated for oral application, topical application or parenteral application.

36. (New) The pharmaceutical composition of claim 31, wherein the composition has a formulation selected from the group consisting of an infusion solution, an injection solution, an orally administrable form, a gelatin-capsule, a tablet, a controlled release tablet, a granulate, a food supplement, an enema, and any combinations thereof.

37. (New) The pharmaceutical composition of claim 31, wherein the composition comprises a neurostimulatory or a neuroprotective composition.

38. (**Withdrawn**) The pharmaceutical composition of claim 31 further comprising at least one neurostimulatory extract of Mucuna pruriens selected from the group consisting of M-PL0100, M-EL100, M-BL0100, LAT543 0, and any combination thereof.

39. (New) The pharmaceutical composition of claim 31 further comprising at least one neuroprotective extract of Mucuna pruriens selected from the group consisting of M-W-EL1299, M-W0100, MWEL0700, M ML0100, and any combination thereof.

40. (New) The pharmaceutical composition of claim 31, wherein the composition is operable to regulate L Dopa by a mechanism selected from the group consisting of inhibiting L-Dopa metabolism, inhibiting dopamine metabolism, improving L-Dopa absorption, quickening the onset of L-Dopa efficacy, increasing the duration of L-Dopa efficacy, and any combinations thereof.

41. (New) The pharmaceutical composition of claim 31, wherein the composition is operable to prevent, treat, or alleviate a neurological disease.

42. (New) The pharmaceutical composition of claim 41, wherein the neurological disease comprises a neurodegenerative disease.

43. (New) The pharmaceutical composition of claim 42, wherein the neurodegenerative disease is selected from the group consisting of: Huntington's disease, Alzheimer's disease, other diseases caused by exogenic factors, other diseases caused by endogenic factors, and any combinations thereof.

44. (New) The pharmaceutical composition of claim 42, wherein the neurodegenerative disease is Parkinson's disease.

45. (New) The pharmaceutical composition of claim 44, wherein the composition is operable to treat Parkinson's disease by preventing acute or chronic L-Dopa toxicity.

46. (New) The pharmaceutical composition of claim 31, wherein component, substance, fraction, or mixture thereof does not contain a pharmaceutically effective amount of L-dopa.

47. (New) The pharmaceutical composition of claim 31, wherein the pharmaceutical composition further comprises at least one additional pharmaceutically active agent.

48. (New) A method of preparing a pharmaceutical composition comprising:

extracting at least one component, substance, fraction, or mixture thereof from a Mucuna pruriens seed; and

adding a pharmaceutically acceptable diluent, excipient or carrier to the component, substance, fraction, or mixture thereof to form a pharmaceutical composition.

49. (New) The method of claim 48, wherein extracting comprises using at least one alcohol or mixture of alcohols selected from the group consisting of hexenol, butanol, ethanol, methanol, isopropanol, n-propanol, and any combinations thereof.

50. (New) The method of claim 48, wherein extracting comprises using at least organic solvent or mixture of organic solvents selected from the group consisting of chloroform, CO2, hypercritical CO2, ether, DMSO, hexane, ethylacetate, dichiormethane, acetone, and any combinations thereof.

51. (New) The method of claim 48, wherein extracting comprises using at least one polar solvent or mixture of polar solvents selected from the group consisting of water, ethanol, methanol, propanol, isopropanol, and any combinations thereof.

52. (New) The method of claim 48, wherein extracting comprises using at least two solvents.

53. (New) The method of claim 48, wherein extracting comprises fractionated extraction.

54. (New) A method of preparing extracts or extract-fractions of Mucuna pruriens seeds comprising extracting a seed of Mucuna pruriens to obtain at least one pharmaceutically active component, substance, fraction, or mixture thereof including an extract or extract fractions.

55. (New) The method of claim 54, wherein extracting comprises:

extracting a seed of Mucuna pruriens with n-hexane to provide a first extract solution;

filtering the first extract solution to provide a first filter retentate;

extracting the first filter retentate with acetone to provide a second extract solution;

filtering the second extract solution to provide a second filter retentate;

extracting the second filter retentate with an approximately 1:1 mixture of water and ethanol containing approximately 0.5% ascorbic acid to provide third extract solution;

filtering the third extract solution to provide a third filter retentate;

repeating the extraction with an approximately 1:1 mixture of water and ethanol containing approximately 0.5% ascorbic acid at least four times using the third through a sixth filter retentate to provide a fourth through seventh extract solutions;

pooling at least two of the extract solutions to provide a pooled extract solution; and

concentrating the pooled extract solution to form an extract or extract fractions.

56. (New) The method of claim 54, wherein extracting comprises:

extracting a seed of Mucuna pruriens with an alcohol to provide an extract solution, wherein the alcohol includes methanol, ethanol, propanol, or a mixture thereof;

filtering the extract solution to provide a retentate;

repeating the extraction and filtering steps using the previous retentate at least two times;

pooling at least two extract solutions to provide a pooled extract solution; and

concentrating the pooled extract solution to form an extract or extract fractions.

57. (New) The method of claim 54, wherein extracting comprises using CO2 or mixtures of CO2 and butane, propane or other gases under supercritical conditions or different pressures and temperatures, to obtain purification and selection of substances or fractionation of Mucuna pruriens extracts.

58. (New) The method of claim 54, further comprising solubilizing the extract or extract fractions in a solvent comprising DMSO, distilled water, or a mixture thereof.

59. (New) The method of claim 54, further comprising the extract or extract fraction in a form selected from the group consisting of comminuted form, in unmodified form, as granules, powder, precipitate, fraction, extract, dried extract, exudate, and any combinations thereof.

60. (New) The method of claim 54, further comprising formulating a pharmaceutical composition from the at least one pharmaceutically active component, substance, fraction, or mixture thereof including the extract or extract fractions.

61. (New) A kit comprising at least one container containing at least one Mucuna pruriens seed component, substance, fraction, or mixture or said pharmaceutical composition of claim 1.